Click TB Consortium completes recruitment for novel oral carbapenem antibiotic

The TASK-009-SANF, a phase 2A clinical trial investigating the use of sanfetrinem cilexetil—an oral carbapenem antibiotic for pulmonary tuberculosis (TB)—has successfully concluded patient enrolment. The last participant’s final visit was recorded on 19 August 2024.

As one of the first proof-of-concept studies for an oral carbapenem in TB, this trial aims to shed light on the potential role of this drug class in tuberculosis treatment. Sanfetrinem cilexetil’s unique ability to kill Mycobacterium tuberculosis (M. tb) in vitro without the need for a beta-lactamase inhibitor like clavulanate sets it apart from other available carbapenems.

By evaluating the early bactericidal activity (EBA), safety, and pharmacokinetics of sanfetrinem cilexetil, the study could pave the way for oral carbapenems to play a more significant role in TB drug development and repurposing efforts.

This EDCTP-funded research is part of the Click TB consortium, led by GSK. Click-TB aims to identify the most promising combinations of TB drugs from a pool of early-stage candidates from new chemical classes.

Statistical analysis is currently underway, with reports expected early in the first quarter of 2025. The findings from this trial will provide valuable insights into the potential of sanfetrinem cilexetil as a promising new treatment option for tuberculosis.